SCHEMBL12704141

SCHEMBL12704141

CC12CCC(=O)C=C1CCC1C2=CCC2(C)C1CC[C@]2(O)C(=O)CO

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 7/20 0.78
CYP19A1 P11511 1/20 0.57
HSD17B10 Q99714 7/20 0.57
CYP2C19 P33261 4/20 0.57
HIF1A Q16665 4/20 0.57
SHBG P04278 3/20 0.57
SERPINA6 P08185 3/20 0.57
CYP3A4 P08684 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
LMNA P02545 2/20 0.57
PMP22 Q01453 2/20 0.57
TSHR P16473 2/20 0.57
BLM P54132 1/20 0.57
ALDH1A1 P00352 2/20 0.56
CYP2D6 P10635 1/20 0.56
KCNA1 Q09470 1/20 0.56
SLC47A1 Q96FL8 1/20 0.56
MAPK1 P28482 1/20 0.55
PGR P06401 2/20 0.52
NR3C2 P08235 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23974907 1.00 NR3C1 (0.78) NR3C1CYP19A1HSD17B10CYP2C19HIF1A
SCHEMBL1274268 1.00 NR3C1 (0.78) NR3C1CYP19A1HSD17B10CYP2C19HIF1A
SCHEMBL722748 1.00 NR3C1 (0.78) NR3C1CYP19A1HSD17B10CYP2C19HIF1A
SCHEMBL23974955 1.00 NR3C1 (0.78) NR3C1CYP19A1HSD17B10CYP2C19HIF1A
SCHEMBL1275108 1.00 NR3C1 (0.78) NR3C1CYP19A1HSD17B10CYP2C19HIF1A
Anecortave Acetate SCHEMBL8472390 0.92 NR3C1 (0.93) NR3C1CYP19A1HSD17B10CYP2C19HIF1A
SCHEMBL9070362 0.92 NR3C1 (0.78) NR3C1CYP19A1HSD17B10CYP2C19HIF1A
SCHEMBL18351260 0.92 NR3C1 (0.78) NR3C1CYP19A1HSD17B10CYP2C19HIF1A
SCHEMBL9223381 0.92 NR3C1 (0.78) NR3C1CYP19A1HSD17B10CYP2C19HIF1A
SCHEMBL9223554 0.92 NR3C1 (0.78) NR3C1CYP19A1HSD17B10CYP2C19HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160326210-A1 Enzymatic Process for Obtaining 17 Alpha-Monoesters of Cortexolone and/or its 9,11-Dehydroderivatives CASSIOPEA S.P.A. (IT) 2016-11-10 US disclosed
US-20160326210-A1 Enzymatic Process for Obtaining 17 Alpha-Monoesters of Cortexolone and/or its 9,11-Dehydroderivatives CASSIOPEA S.P.A. (IT) 2016-11-10 US disclosed
US-20160324873-A1 Enzymatic Process for Obtaining 17 Alpha-Monoesters of Cortexolone and/or its 9,11-Dehydroderivatives CASSIOPEA S.P.A. (IT) 2016-11-10 US disclosed
US-20160324873-A1 Enzymatic Process for Obtaining 17 Alpha-Monoesters of Cortexolone and/or its 9,11-Dehydroderivatives CASSIOPEA S.P.A. (IT) 2016-11-10 US disclosed
US-9486458-B2 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives CASSIOPEA SPA (IT) 2016-11-08 US disclosed
US-9486458-B2 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives CASSIOPEA SPA (IT) 2016-11-08 US disclosed
US-9433628-B2 Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives CASSIOPEA SPA (IT) 2016-09-06 US disclosed
US-9433628-B2 Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives CASSIOPEA SPA (IT) 2016-09-06 US disclosed
EP-2503005-B1 Cortexolone-17alpha-propionate in hydrate crystalline form IV CASSIOPEA S P A (IT) 2015-09-02 EP disclosed
US-8785427-B2 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives COSMO DERMATOS SRL (IT) 2014-07-22 US disclosed
US-8785427-B2 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives COSMO DERMATOS SRL (IT) 2014-07-22 US disclosed
US-20140179654-A1 ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA- MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11- DEHYDRODERIVATIVES COSMO SPA (IT) 2014-06-26 US disclosed
US-20140179654-A1 ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA- MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11- DEHYDRODERIVATIVES COSMO SPA (IT) 2014-06-26 US disclosed
US-20110092472-A1 ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA- MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11- DEHYDRODERIVATIVES COSMO SPA (IT) 2011-04-21 US disclosed
US-20110092472-A1 ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA- MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11- DEHYDRODERIVATIVES COSMO SPA (IT) 2011-04-21 US disclosed
WO-2009019138-A2 ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA-MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVES COSMO SPA (IT) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092472-A1 ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA- MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11- DEHYDRODERIVATIVES CYP17A1, HSD17B1, HSD11B1 NR3C1 264/4885CYP19A1 26/4885HSD17B10 22/4885
US-20160324873-A1 Enzymatic Process for Obtaining 17 Alpha-Monoesters of Cortexolone and/or its 9,11-Dehydroderivatives CYP17A1, HSD17B1, HSD11B1 NR3C1 272/4885CYP19A1 25/4885HSD17B10 21/4885
US-20140179654-A1 ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA- MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11- DEHYDRODERIVATIVES CYP17A1, HSD17B1, HSD11B1 NR3C1 264/4885CYP19A1 26/4885HSD17B10 22/4885
US-20160326210-A1 Enzymatic Process for Obtaining 17 Alpha-Monoesters of Cortexolone and/or its 9,11-Dehydroderivatives CYP17A1, HSD17B1, HSD11B1 NR3C1 272/4885CYP19A1 25/4885HSD17B10 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.